Resistance enzyme inhibitors
Our products prevent bacterial enzymes from destroying antibiotics
Our inhibitors target beta-lactamases not covered by inhibitors on the market
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Outsource
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- BSI
- IAI
- STI
- RTI
- GII
- SSTI
- CNSI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
A partner must contribute with competence and funding for late-stage clinical development. A partner may also be distributor in certain markets.
Adjutec is a biotech company developing beta-lactamase inhibitor to overcome the alarming increase in antimicrobial resistance.
Adjutec is supporting academic research in the field of new antibiotics
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!